Roos, I. Et Al. 2022. A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis. 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis , (Amsterdam, Netherlands), 951-953.

Roos, I., Hughes, S., MacDonnell, G., Boz, C., Alroughani, R., Ozakbas, S., ... Buzzard, K.(2022). A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis . 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (pp.951-953). Amsterdam, Netherlands

Roos, I. Et Al. "A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis," 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 2022

Roos, I. Et Al. "A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis." 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis , Amsterdam, Netherlands, pp.951-953, 2022

Roos, I. Et Al. (2022) . "A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis." 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis , Amsterdam, Netherlands, pp.951-953.

@conferencepaper{conferencepaper, author={I. Roos Et Al. }, title={A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis}, congress name={38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis}, city={Amsterdam}, country={Netherlands}, year={2022}, pages={951-953} }